The Georgia Board of Pardons and Paroles convened Monday to hear the case of William Earl Lynd, who is scheduled to die Tuesday for fatally shooting his live-in girlfriend, Ginger Moore, two days before Christmas in 1988.

Lynd's attorney, Tom Dunn, is seeking a 90-day stay of execution as well as a commutation of his sentence.

The U.S. Supreme Court in April upheld Kentucky's lethal injection protocol, clearing the way for executions to resume in the roughly three dozen states that use that method.

Kreuscher (CROY'-shir) says the new name would symbolize the help God gave him through tough times.

The 57-year-old man also told the (Arlington Heights) Daily Herald he's worried that atheists may succeed in removing the phrase "In God We Trust" from U.S. currency.

He recalls that the phrase "God Reigns" was removed from the Zion city seal in 1992 after courts deemed it unconstitutional. Zion was founded as a theocracy — by a sect that believed the Earth was flat.

The school bus driver and amateur artist in the northern Chicago suburb says he has filed a petition to change his name in Lake County Circuit Court.

Torkelsen, who is in federal custody awaiting sentencing on an unrelated case, pleaded guilty to one count of perjury in connection with a 1999 declaration to a San Jose federal court, according to U.S. prosecutors in Philadelphia. He faces up to five years in prison on the charge, and is set to be sentenced on Aug. 5. An attorney for Torkelsen was not immediately available for comment.

Prosecutors said the law firms told courts and class members that Torkelsen was being paid as an independent expert but secretly paid him a share of the proceeds of the cases.

Under the agreement, Parmalat will issue to class members 10.5 million existing shares "in full satisfaction of any and all claim asserted against it in the class action, worldwide," the company said in a statement. Those shares would be valued at $36.8 million at the current market price.

Parmalat will also pay up to 1 million euros ($1.55 million) of the cost of notifying the class members of the settlement, the statement said.

The lawsuit was brought on behalf of former Parmalat shareholders and other investors, who claimed they were damaged by Parmalat's 2003 collapse.

The settlement removes the threat of a suit that had been weighing on the Italian company's stock. Parmalat shares jumped on the news and by late morning they were trading up 2.6 percent at 2.25 euros ($3.50), outperforming an overall positive market.

Oregon's high court ruled unanimously Thursday that smokers must show actual harm to make a negligence claim against cigarette manufacturers — not just the possibility they will be harmed.

The lawsuit, brought by Patricia Lowe on behalf of about 400,000 Oregonians, argued the tobacco companies were negligent because they "knew or should have known that their cigarettes contained toxic and hazardous substances likely to cause lung cancer."

Lowe argued the industry should pay for tests to detect lung tumors at their earliest and most treatable stage.

The court ruled instead that Oregon law has long recognized that "a threat of future physical harm is not sufficient" grounds for a legal claim.

James Coon, who represents Lowe, said the ruling shows the law is trailing behind science.

"Certain toxic products put people at risk for future injury," Coon said, but "medical monitoring is a concept that ancient common law has trouble dealing with, and the court in this case applied old common law concepts without flexing them in any way."

Carl Tobias, a University of Richmond law professor who specializes in torts, or damage claims, agreed.

"It doesn't fit in the box of traditional tort law," Tobias said. "Tort law by definition is after the fact. It aims primarily to compensate for past harm — not to prevent future harm."

But Tobias noted that Justice Martha Lee Walters, in a concurring opinion, left open the possibility the law could change "when science and medicine are able to identify harm before it becomes manifest."

Such techniques may be coming soon, said Thomas Glynn, the American Cancer Society's cancer science and trends director.

"We're probably about two years away before we can say whether we can detect lesions early enough to know what the effect will be," Glynn said.

Ben Zipursky, a Fordham University School of Law professor who specializes in product liability, said it was ironic the ruling came from the same court that recently affirmed a nearly $80 million punitive damages award against tobacco giant Philip Morris after it was struck down by the U.S. Supreme Court.

"This is the very court that has most aggressively ruled against Philip Morris," Zipursky said.

The ruling was similar to those in state courts around the nation in similar cases, despite a move toward loosening the definition of actual harm, he said.

Philip Morris and R.J. Reynolds Tobacco Co., two of the five companies named in the lawsuit, welcomed the ruling in a statement released Thursday.

The other companies were Brown & Williamson Tobacco Corp., Lorillard Tobacco Co. and Liggett Group Inc.

The Court of Appeal ruled that the National Institute for Health and Clinical Excellence (NICE) -- the body that controls the prescription of new drugs -- must be more transparent about how it calculates the cost-effectiveness of new treatments.

In a ruling delivered Thursday, the judges found the process by which NICE decided to restrict Alzheimer's drug Aricept to patients with a moderate version of the degenerative brain disease "was procedurally unfair".

They added that NICE should release a full version of the cost-effectiveness model used to produce guidance for the drugs.

NICE had decided in 2004 that the drugs, which cost about £2.50 a day and slow down the progress of the disease, are not cost-effective for patients in the early stages of Alzheimer's. This decision was upheld by a court in 2007.

Drug companies Eisai Ltd and Pfizer Ltd, which challenged the NICE decision, welcomed the Court of Appeal's ruling, saying it brought new hope for Alzheimer's patients.

Nick Burgin, managing director of Eisai, said: "We believe that this decision represents a victory for common sense. As soon as we have reviewed their cost-effectiveness calculations we will submit any new findings to NICE.

"We hope that this action will ultimately restore access to anti-dementia medicines for those patients at the mild stages of Alzheimer's disease."

NICE chief executive Andrew Dillon said: "We will be considering very carefully the findings and the implications for the time it takes us to provide advice to patients and the NHS on the use of new treatments.

"It is important to recognise that we have not been asked to amend or withdraw our current guidance on the use of these drugs to treat Alzheimer's disease: the drugs continue to be recommended only for people with moderate Alzheimer's disease."

Neil Hunt, chief executive of the Alzheimer's Society said: "Today's decision is a damning indictment of the fundamentally flawed process used by NICE to deny people with Alzheimer's disease access to drug treatments."

Alzheimer's disease is the most common form of dementia, affecting around 417,000 people in the UK.